Discover Our Science
At DeepVax, we strive to pioneer an innovative approach for developing therapeutic vaccines by leveraging immunologically and structurally optimized VLPs.
Virus Like Particles
Our platform is based on virus-like particles (VLPs), we use virally shaped nanoparticles as a scaffold for the generation of tailor-made therapeutic vaccines against CHRONIC DISEASES.
VLPs are safe and non-infectious, as they lack genetic material. Their nanoparticle structure mimics a viral threat, prompting a strong immune response against the displayed antigen. VLPs are effective vaccine platforms and have been used to target infections, chronic diseases. Toll-like receptor (TLR) ligands can be incorporated into VLPs during production in bacterial cells, significantly enhancing immune responses.
Molecular Modeling
Utilizing the latest molecular technologies, including AlphaFold—an AI-guided molecular design tool awarded the Nobel Prize—we optimize our vaccine candidates immunologically, physically, chemically, and structurally to maximize protective immune responses.
Therapeutic Vaccines
Monoclonal antibodies are a groundbreaking yet expensive class of disease-modifying drugs. At DeepVax, we have developed an innovative technology based on immunologically optimized virus-like particles (VLPs). This approach enables us to stimulate the body’s production of antibodies against disease-causing endogenous molecules, moving from passive antibody therapy to active immunization with VLP-based vaccines. This shift not only reduces production costs significantly but also enhances patient convenience. Through this technology, we aim to greatly expand access to disease-modifying therapies for patients and communities with limited financial resources.